Loading…
Based on limited available metadata, an FDA Warning Letter was issued to Haw Par Healthcare Limited on August 19, 2019, regarding drug products. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be determined from this metadata alone. The warning falls under FDA's drug product regulatory authority, though the specific issuing office and violation details remain unavailable in this summary. Additional documentation would be needed to identify the specific compliance issues that prompted this enforcement action.